NNVC

NanoViricides Inc

1.32

Nov 06 • 3:59 PM ET +0.03 (2.33%)

1.31

Aftermarket • 7:30 PM ET -0.01 (-0.76%)

Healthcare Biotechnology USA Nano AMEX

Peers: COCP ALGS ENTA TRAW AVIR IVVD SIGA VIR TNXP EBS

| Held by: VTI VXF BUSM

Scroll to Statements

Index	-
Market Cap	33.69M
Enterprise Value	30.90M
Income	-8.22M
Sales	0.00M
Book/sh	0.38
Cash/sh	0.11
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	7
IPO	Aug 12, 2004

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.50
P/C	12.08
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	2.66
Current Ratio	2.66
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / No

EPS (ttm)	-0.41
EPS next Y	-
EPS next Q	-0.10
EPS this Y	-6.98%
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	18.01% 12.84%
Sales past 3/5Y	- -
EPS Y/Y TTM	35.47%
Sales Y/Y TTM	-
EPS Q/Q	21.51%
Sales Q/Q	-
Earnings	Sep 02
EPS/Sales Surpr.	-10.00% -

Insider Own	2.49%
Insider Trans	0.00%
Inst Own	9.38%
Inst Trans	2.11%
ROA	-87.91%
ROE	-101.46%
ROIC	-94.65%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-4.14%
SMA50	-0.17%
SMA200	1.95%
Trades

Shs Outstand	25.52M
Shs Float	24.89M
Short Float	4.59%
Short Ratio	3.01
Short Interest	1.14M
52W High	2.11 -37.44%
52W Low	0.85 55.29%
Volatility	6.86% 7.36%
ATR (14)	0.11
RSI (14)	46.81
Beta	1.82
Rel Volume	0.32
Avg Volume	379.94K
Volume	121,393

Perf Week	-0.75%
Perf Month	0.76%
Perf Quarter	-5.71%
Perf Half Y	-14.84%
Perf YTD	16.81%
Perf Year	-30.53%
Perf 3Y	15.79%
Perf 5Y	-72.09%
Perf 10Y	-94.84%
Recom	1.00
Target Price	6.00
Prev Close	1.29
Price	1.32
Change %	2.33%

Consensus

Strong Buy

Avg. Price Target

$6.00

Implied Upside

+354.5%

Analysts2incl. previous ratings

Rating Distribution2 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Dec 16, 2025	Initiated	AAlliance Global Partners	Buy
Feb 11, 2015	Initiated	MMidtown Partners	Strong Buy	$5.30	+301.5%

Oct-27-26 09:15AM	As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides (ACCESSWIRE) +7.35%
Oct-20-26 08:45AM	NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials (ACCESSWIRE) +13.85%
Oct-13-26 08:45AM	Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides (ACCESSWIRE)
Oct-06-26 08:45AM	NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026 (ACCESSWIRE)
Oct-05-26 08:45AM	NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives (ACCESSWIRE) +13.28%
08:45AM	Loading…
Sep-29-26 08:45AM	NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials (ACCESSWIRE) -13.33%
Sep-28-26 04:48PM	NanoViricides: Fiscal Q4 Earnings Snapshot (Associated Press)
08:45AM	Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides (ACCESSWIRE)
Sep-23-26 08:30AM	Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides (ACCESSWIRE)
Sep-15-26 09:25AM	Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in ?DR Congo with 48% Crude Fatality Rate, Says NanoViricides (ACCESSWIRE)
Sep-08-26 08:30AM	Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo (ACCESSWIRE)
Aug-31-26 08:30AM	While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles (ACCESSWIRE)
Aug-18-26 08:30AM	The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon (ACCESSWIRE)
Aug-10-26 08:30AM	NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak (ACCESSWIRE)
Jul-28-26 08:30AM	NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial (ACCESSWIRE)
08:00AM	Loading…
Jul-24-26 08:00AM	NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering (ACCESSWIRE)
Jul-22-26 08:30AM	As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola (ACCESSWIRE) -5.00%
Jul-13-26 09:27AM	As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo (ACCESSWIRE) +9.27%
Jul-08-26 08:30AM	Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily (ACCESSWIRE) +5.44%
Jul-06-26 01:27PM	NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential Everything To Know About Its Experimental Drug For Ebola (Stocktwits) +12.78%
08:30AM	As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo (ACCESSWIRE)
Jun-29-26 08:30AM	US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher (ACCESSWIRE)
Jun-25-26 09:00AM	REPLAY: Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan (Ipo Edge)
Jun-22-26 09:30AM	NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo (ACCESSWIRE) -5.71%
Jun-15-26 08:30AM	As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo (ACCESSWIRE) +15.57%
Jun-08-26 08:30AM	As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies (ACCESSWIRE)
May-26-26 08:30AM	In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides (ACCESSWIRE) -7.93%
May-19-26 09:06AM	NanoViricides closes $2M direct offering (Proactive) +5.30%
08:11AM	Nasdaq semis lead losses as bond yields put pressure on Iran talks (Proactive)
May-18-26 11:55PM	NanoViricides Announces Closing of ~$2 Million Registered Direct Offering (ACCESSWIRE)
08:34AM	Loading…
08:34AM	NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak (Proactive)
08:30AM	Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides (ACCESSWIRE)
May-15-26 10:02AM	NanoViricides to raise $2M in registered direct offering (Proactive) -14.94%
08:35AM	NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering (ACCESSWIRE)
08:00AM	NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II (ACCESSWIRE)
06:18AM	NanoViricides: Fiscal Q3 Earnings Snapshot (Associated Press)
May-12-26 08:35AM	Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs (Exec Edge)
May-11-26 09:00AM	NanoViricides says Phase I antiviral drug could address gap exposed by hantavirus cruise ship outbreak (Proactive)
08:30AM	Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides (ACCESSWIRE)
May-07-26 08:35AM	NanoViricides to Participate at D. Boral Capital Global Conference in NYC (Exec Edge)
May-06-26 03:37PM	NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference (Newsfile)
08:35AM	NanoViricides Measles Treatment Granted Orphan Drug Designation by FDA (Exec Edge)
May-04-26 09:00AM	NanoViricides antiviral drug NV-387 wins FDA Orphan Drug Designation for measles treatment (Proactive) +15.38%
08:30AM	NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA (ACCESSWIRE)
Apr-21-26 09:10AM	NanoViricides says NV-387 could address measles outbreaks as cases rise globally (Proactive)
08:30AM	Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides (ACCESSWIRE)
Apr-11-26 06:22AM	NanoViricides seeks FDAs rare pediatric disease designation for antiviral candidate NV-387 - ICYMI (Proactive)
Apr-09-26 11:24AM	NanoViricides files for Rare Pediatric Disease Designation for Measles Drug (Proactive)
Apr-07-26 09:05AM	NanoViricides seeks rare pediatric disease status for measles drug NV-387 (Proactive) +6.93%
08:30AM	Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides (ACCESSWIRE)
Apr-01-26 09:15AM	NanoViricides to begin Phase II trial of MPox treatment in Congo (Proactive)
08:30AM	Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides (ACCESSWIRE)
Mar-11-26 03:43PM	Dow down, Nasdaq flat as Oracle lifts tech but Gulf shipping attacks eyed (Proactive) +18.32%
09:20AM	NanoViricides completes manufacturing of NV-387 oral drug ahead of Phase II mpox trial (Proactive)
08:30AM	NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete (ACCESSWIRE)
Feb-21-26 11:00AM	NanoViricides CEO discusses progress of broad-spectrum antiviral candidate NV-387 - ICYMI (Proactive)
Feb-19-26 03:30PM	Dow Jones leads Wall Street lower, US-Iran fears drive oil higher (Proactive)
08:27AM	NanoViricides advances broad-spectrum antiviral NV-387 towards Phase II MPox study (Proactive)
Feb-18-26 06:01PM	NanoViricides advances toward fully funded Phase II MPox trial in DRC (Proactive)
Feb-17-26 04:54PM	NanoViricides: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
Feb-12-26 03:50PM	Dow drops below 50,000 as S&P 500 falls back under years opening level (Proactive) -7.92%
09:23AM	NanoViricides seeks FDA orphan status for MPox drug (Proactive)
08:30AM	MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides (ACCESSWIRE)
Feb-10-26 09:13AM	NanoViricides seeks orphan drug status with US FDA for measles treatment (Proactive) +8.02%
08:30AM	Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides (ACCESSWIRE)
Feb-02-26 08:30AM	NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres (ACCESSWIRE)
Jan-13-26 08:30AM	NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2 (ACCESSWIRE) +6.19%
Dec-12-25 09:51AM	2 Small-Cap Biotechs That Could Reward Patient Investors (MarketBeat)
Dec-01-25 08:30AM	NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles (ACCESSWIRE) -8.20%
Nov-17-25 08:30AM	NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position (ACCESSWIRE)
Nov-14-25 05:41PM	NanoViricides: Fiscal Q1 Earnings Snapshot (Associated Press Finance) +5.19%
08:30AM	NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2 (ACCESSWIRE)
Nov-12-25 05:01PM	NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close (ACCESSWIRE) -5.66% -10.00%
Nov-11-25 08:30AM	NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close (ACCESSWIRE) -5.36%
Nov-10-25 08:30AM	NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo (ACCESSWIRE) -8.70%
Nov-05-25 08:30AM	NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT (ACCESSWIRE)
Nov-03-25 08:30AM	NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd (ACCESSWIRE) +22.29%
Oct-29-25 08:45AM	Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive (ACCESSWIRE) +21.57%
Oct-27-25 08:45AM	NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 (ACCESSWIRE) +5.23%
Oct-22-25 08:45AM	In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides (ACCESSWIRE)
Oct-20-25 08:45AM	A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus (ACCESSWIRE)
Oct-15-25 08:45AM	NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses (ACCESSWIRE) +6.67%
Sep-30-25 08:45AM	NanoViricides, Inc. Has Filed its Annual Report (ACCESSWIRE)
Sep-11-25 08:30AM	RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025 (ACCESSWIRE)
Sep-09-25 08:30AM	NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025 (ACCESSWIRE)
Aug-18-25 08:30AM	A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials (ACCESSWIRE)
Jul-30-25 08:30AM	Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides (ACCESSWIRE)
Jul-23-25 08:30AM	NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value (ACCESSWIRE)
Jul-21-25 06:30AM	Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides (ACCESSWIRE)
Jul-16-25 08:30AM	WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides (ACCESSWIRE) +9.59%
Jul-14-25 06:30AM	Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides (ACCESSWIRE) +14.70%
Jul-01-25 06:30AM	There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate (ACCESSWIRE)
Jun-18-25 06:30AM	With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan (ACCESSWIRE)
Jun-04-25 06:55AM	NanoViricides Measles Drug Development Animal Study is Imminent (ACCESSWIRE) +6.80%
May-28-25 06:30AM	NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025 (ACCESSWIRE)
May-22-25 06:30AM	The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan (ACCESSWIRE)
May-16-25 06:30AM	NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu (ACCESSWIRE) +7.63%
May-15-25 05:16PM	NanoViricides: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
May-14-25 06:30AM	Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution (ACCESSWIRE)
May-08-25 06:30AM	Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo (ACCESSWIRE) +13.71%

Show Previous News

NanoViricides, Inc. is a clinical stage company, which engages in the development of nano-biopharmaceutical drugs against viruses. It focuses on anti-viral therapeutics through internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.

Executive ChairmanDr. Anil R. Diwan Ph.D.

M.B.A.Ms. Meeta R. Vyas B.S.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NNVC

NanoViricides Inc

Upgrade your Finviz experience